Park National Corp OH reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 339,020 shares of the company’s stock after selling 4,257 shares during the quarter. Johnson & Johnson makes up approximately 2.6% of Park National Corp OH’s portfolio, making the stock its 6th largest position. Park National Corp OH’s holdings in Johnson & Johnson were worth $47,219,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Evolution Wealth Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter worth $40,000. Horan Securities Inc. lifted its stake in shares of Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after acquiring an additional 241 shares during the period. Stuart Chaussee & Associates Inc. lifted its stake in shares of Johnson & Johnson by 20.7% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 80 shares during the period. FNY Investment Advisers LLC lifted its stake in shares of Johnson & Johnson by 594.4% in the fourth quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after acquiring an additional 428 shares during the period. Finally, Thor Advisors LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth approximately $69,000. Hedge funds and other institutional investors own 66.83% of the company’s stock.
Shares of NYSE:JNJ traded up $0.20 during midday trading on Tuesday, reaching $128.84. 5,562,258 shares of the company traded hands, compared to its average volume of 7,014,447. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The company has a market capitalization of $345.98 billion, a price-to-earnings ratio of 15.75, a price-to-earnings-growth ratio of 2.20 and a beta of 0.70. The business’s fifty day moving average price is $138.25.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.10 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.95%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $139.68 per share, with a total value of $419,040.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.23% of the stock is currently owned by company insiders.
Several research firms have weighed in on JNJ. BMO Capital Markets began coverage on Yelp in a research report on Wednesday, April 17th. They issued an “outperform” rating on the stock. Raymond James reissued a “reduce” rating and issued a $48.00 price objective (up previously from $45.00) on shares of Hancock Whitney in a research report on Wednesday, July 17th. Morgan Stanley set a $60.00 price target on Berry Global Group and gave the company a “hold” rating in a research report on Wednesday, April 17th. Royal Bank of Canada upped their price target on Johnson Service Group from GBX 180 ($2.35) to GBX 190 ($2.48) and gave the company an “outperform” rating in a research report on Tuesday, July 16th. Finally, Wells Fargo & Co upped their price target on Wingstop from $76.00 to $84.00 and gave the company an “outperform” rating in a research report on Monday, May 6th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $148.56.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Google Finance Portfolio
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.